Literature DB >> 10585806

Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients.

R Nüesch1, C Bellini, W Zimmerli.   

Abstract

For 89 human immunodeficiency virus (HIV)-positive and 32 HIV-negative immunocompromised patients who had 121 episodes of Pneumocystis carinii pneumonia (PCP), clinical features and changes over time were compared. HIV-infected patients characteristically had a longer duration of symptoms (23 vs. 13 days; P<.005); were younger (39 vs. 48 years; P<.001); had a higher frequency of sweating, weight loss, and thoracic pain; and had fewer admissions to the intensive care unit (16% vs. 31%; P<.05). In addition, they had significantly higher hemoglobin levels, lower thrombocyte counts, lower C-reactive protein values, and a higher proportion of eosinophils and lymphocytes in bronchoalveolar lavage fluid. After 1995, HIV-negative patients' mean length of stay dropped from 34 days to 16 days (P<.005), and their hospital mortality rate dropped from 29% to 7% (P<.001). HIV-positive patients with PCP differed in several aspects from those without HIV infection. Knowledge gained from experience with treatment of opportunistic infections in patients with AIDS has improved the management of PCP in patients with other immunodeficiencies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585806     DOI: 10.1086/313534

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

2.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

3.  Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons.

Authors:  J A McKinnell; A P Cannella; D F Kunz; E W Hook; S A Moser; L G Miller; J W Baddley; P G Pappas
Journal:  Transpl Infect Dis       Date:  2012-05-01       Impact factor: 2.228

Review 4.  Pneumocystis colonization, airway inflammation, and pulmonary function decline in acquired immunodeficiency syndrome.

Authors:  Karen A Norris; Alison Morris; Sangita Patil; Eustace Fernandes
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 5.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Genetic variation at the mitochondrial large-subunit rRNA locus of Pneumocystis isolates from simian immunodeficiency virus-infected rhesus macaques.

Authors:  Karen A Norris; Hans Wildschutte; Jennifer Franko; Kathryn F Board
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

7.  [Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

8.  Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient.

Authors:  Jordan Y Z Li; Tuck Y Yong; David I Grove; P Toby H Coates
Journal:  Clin Exp Nephrol       Date:  2008-08-30       Impact factor: 2.801

9.  Adjunctive glucocorticoid therapy for non-HIV-related pneumocystis carinii pneumonia (NH-PCP).

Authors:  J A McKinnell; A P Cannella; P Injean; A Gregson
Journal:  Am J Transplant       Date:  2014-02-19       Impact factor: 8.086

10.  Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.

Authors:  Stine Grønseth; Tormod Rogne; Raisa Hannula; Bjørn Olav Åsvold; Jan Egil Afset; Jan Kristian Damås
Journal:  BMC Infect Dis       Date:  2021-07-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.